2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-145430
    IL-17A modulator-1 2748749-29-1 98.80%
    IL-17A modulator-1 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 9. IL-17A modulator-1 inhibits the biological action of IL-17A with a pIC50 of 8.2. IL-17A modulator-1 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders.
    IL-17A modulator-1
  • HY-148123
    Glycerophospholipids, cephalins 39382-08-6
    Glycerophospholipids and cephalins are a class of phospholipid compounds and important components of neural membranes. Glycerophospholipids and cephalins are hydrolysis substrates of phospholipase (such as PLA2, PLC, and PLD). After complete hydrolysis, they produce 1 mol of glycerol, phosphate, ethanolamine, and 2 mol of fatty acids, respectively. Glycerophospholipids and cephalins can maintain membrane structure, fluidity, and ion permeability, and serve as precursors of second messengers such as arachidonic acid and diacylglycerol. Glycerophospholipids and cephalins can regulate signal transduction, cell apoptosis, and membrane transport, and are used in the study of neurodegenerative diseases (such as Alzheimer's disease).
    Glycerophospholipids, cephalins
  • HY-148502
    VU6019650 2926782-31-0 98.61%
    VU6019650 is a potent and selective orthosteric antagonist of M5 mAChR (IC50=36 nM), can be used for opioid use disorder (OUD) relief. VU6019650 can cross blood brain barrier, potentially modulates the mesolimbic dopaminergic reward circuitry. VU6019650 blocks Oxotremorine M iodide (HY-101372A) induced increases of neuronal firing rates of midbrain dopamine neurons in the ventral tegmental area (VTA).
    VU6019650
  • HY-149170
    FFN246 2210244-83-8 99.79%
    FFN246 is a fluorescent, dual substrate of serotonin transporter (SERT) probe and vesicular monoamine transporter 2 (VMAT2) with excitation and emission spectra 392/427 nm. FFN246 can be used for labeling serotonergic neurons in mouse brain tissue through SERT-dependent accumulation.
    FFN246
  • HY-153584
    MRK-898 461450-30-6 99.48%
    MRK-898 is an orally active GABA(A) receptor modulator. MRK-898 binds to α1, α2, α3 or α5 subunit of GABA(A) receptor with Ki values of 1.2 nM, 1.0 nM, 0.73 nM, and 0.50 nM, respectively. However, α1-containing GABA(A) receptors are identified as the "sedative" and α2- and/or α3-containing receptors as the "anxiolytic" subtype(s).
    MRK-898
  • HY-15419A
    RS-127445 199864-87-4 99.62%
    RS-127445 is a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist with a pKi of 9.5. RS-127445 shows 1000 fold selectivity for this receptor as compared to numerous other receptor and ion channel binding sites.
    RS-127445
  • HY-154851
    GSK-3 inhibitor 3 2227279-84-5 98.72%
    GSK-3 inhibitor 3 is a selective, orally active and brain-penetrant inhibitor of GSK-3, with IC50s of 0.35 nM and 0.25 nM for GSK-3α and GSK-3β, respectively. GSK-3 inhibitor 3 lowers levels of tau protein phosphorylation at S396 in a triple-transgenic mouse Alzheimer’s disease model, with IC50 of 10 nM. GSK-3 inhibitor 3 can be used for neurological disease research.
    GSK-3 inhibitor 3
  • HY-155659
    4A7C-301 99.86%
    4A7C-301 is a Nurr1 agonist with robust neuroprotective effects in vitro. 4A7C-301 significantly ameliorates neuropathological abnormalities and improves motor and olfactory dysfunctions in AAV2-mediated α-synuclein-overexpressing male mouse models. 4A7C-301 can be used for the research of Parkinson’s disease.
    4A7C-301
  • HY-156647
    Usnoflast 2455519-86-3 98.29%
    Usnoflast is the selective, orally active inhibitor for NLRP3 that blocks the release of IL-1β, and exhibits anti-inflammatory activity.
    Usnoflast
  • HY-157784
    XPC-7724 98%
    XPC-7724 is a selective Nav1.6 channel inhibitor with a IC50 value of 0.078 μM. XPC-7724 can be used in the study of neurological diseases.
    XPC-7724
  • HY-158024
    NDT-19795 2272917-12-9 99.16%
    NDT-19795 is an effective inhibitor of the NLRP3 inflammasome with an IC50 value of 66 nM in the PBMC method and 4.7 μM in the WB method. NDT-19795 is a carboxylic acid-active substance that can be converted from NT-0796 (HY-156438) within cells. NDT-19795 can be used for the study of neurological diseases.
    NDT-19795
  • HY-158202
    ATF4-IN-2 2991057-60-2 99.24%
    ATF4-IN-2 (Compound 29) is a ATF4 inhibitor with a IC50 value of 47.71 nM. ATF4-IN-2 can be used in the study of neurodegenerative diseases.
    ATF4-IN-2
  • HY-16579A
    Etifoxine 21715-46-8 99.96%
    Etifoxine, a non-benzodiazepine GABAergic compound, is a positive allosteric modulator of α1β2γ2 and α1β3γ2 subunit-containing GABAA receptors. Etifoxine reveals anxiolytic and anticonvulsant properties in rodents.
    Etifoxine
  • HY-19057A
    Vatinoxan hydrochloride 130466-38-5 99.89%
    Vatinoxan hydrochloride (MK-467 hydrochloride;L-659066 hydrochloride) is a peripheral α2 adrenergic receptor antagonist.
    Vatinoxan hydrochloride
  • HY-19818A
    NAN-190 hydrobromide 115338-32-4 99.11%
    NAN-190 hydrobromide is a serotonin receptor 5-HT antagonist. NAN-190 is a selective antagonist of 5-HT1A.
    NAN-190 hydrobromide
  • HY-59201A
    A-582941 dihydrochloride 848591-90-2 99.78%
    A-582941 dihydrochloride is a potent, selective and brain-penetrant partial agonist of α7 nAChR, with Kis of 10.8 and 16.7 nM in rat brain membranes and human frontal cortex, respectively. A-582941 dihydrochloride also binds to human 5-HT3 receptor with a Ki of 150 nM. A-582941 has the potential for cognitive deficits associated with various neurodegenerative and psychiatric disorders research.
    A-582941 dihydrochloride
  • HY-B0304A
    Dapoxetine hydrochloride 129938-20-1 99.96%
    Dapoxetine (LY-210448) hydrochloride is an orally active and selective serotonin reuptake inhibitor (SSRI). Dapoxetine hydrochloride can be used for the research of premature ejaculation (PE).
    Dapoxetine hydrochloride
  • HY-B0546A
    Procaine hydrochloride 51-05-8
    Procaine hydrochloride is a DNA-demethylating agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action.
    Procaine hydrochloride
  • HY-B1626A
    Demecarium Bromide 56-94-0
    Demecarium Bromide (BC-48) is a potent cholinesterase inhibitor, with an apparent affinity (Kiapp) of 0.15 μM. Demecarium Bromide (BC-48) is used as a glaucoma agent.
    Demecarium Bromide
  • HY-B1657A
    Fosphenytoin disodium 92134-98-0 99.81%
    Fosphenytoin sodium is a phenytoin proagent with similar anticonvulsant properties. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
    Fosphenytoin disodium
Cat. No. Product Name / Synonyms Application Reactivity